Korro Bio announces participation in September conferences, focusing on RNA editing therapies for various diseases.
Quiver AI Summary
Korro Bio, Inc. announced its participation in several investor and scientific conferences throughout September 2025, highlighting the involvement of key executives including CEO Dr. Ram Aiyar and CSO Dr. Loic Vincent in various 1x1 meetings and presentations. Notable events include a fireside chat at the Cantor Global Healthcare Conference, and a presentation on RNA editing therapies at the RNA Leaders USA Congress. Korro Bio, based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on RNA editing as a new class of genetic medicine aimed at treating both rare and prevalent diseases. The company emphasizes its innovative approach of editing RNA rather than DNA to enhance specificity and tolerability, aiming to develop therapies that leverage its proprietary platform. For further updates, Korro encourages investors to monitor its Investor Relations website and social media channels.
Potential Positives
- Korro Bio is actively engaging with investors and the scientific community by participating in multiple prestigious conferences, indicating a commitment to transparency and investor relations.
- The company will showcase its innovative RNA editing therapies at prominent forums, potentially attracting interest from investors and collaborators in the biotech space.
- Highlighting the participation of key executives suggests strong leadership visibility, which can enhance investor confidence in the company's direction and capabilities.
- Korro's focus on developing a new class of genetic medicines positions it at the forefront of a transformative area in healthcare, suggesting future growth potential and relevance in market trends.
Potential Negatives
- Participation in multiple investor conferences may indicate a need for increased investor engagement, suggesting potential concerns about the company's market perception or stock performance.
- The focus on RNA editing therapies, while innovative, may raise questions regarding the viability and success of development in a competitive biopharmaceutical landscape.
- The mention of using social media as a primary channel for disclosing material information could be seen as a potential risk for miscommunication or information dissemination issues.
FAQ
What conferences will Korro Bio participate in September 2025?
Korro Bio will attend the Citi Biopharma Conference, Cantor Global Healthcare Conference, and more this September.
Who will represent Korro Bio at the Cantor Global Healthcare Conference?
Dr. Ram Aiyar and Vineet Agarwal will represent Korro Bio at the Cantor Global Healthcare Conference.
Where is Korro Bio based?
Korro Bio is based in Cambridge, Massachusetts.
What recent advancements is Korro Bio focusing on?
Korro Bio is focusing on developing RNA editing therapies for rare and prevalent diseases.
How can investors stay updated on Korro Bio?
Investors can follow Korro Bio on its Investor Relations website, LinkedIn, and X (Twitter) for updates.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KRRO Hedge Fund Activity
We have seen 35 institutional investors add shares of $KRRO stock to their portfolio, and 45 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. removed 680,517 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $8,499,657
- DEEP TRACK CAPITAL, LP removed 596,648 shares (-68.2%) from their portfolio in Q2 2025, for an estimated $7,452,133
- MILLENNIUM MANAGEMENT LLC added 146,814 shares (+134.9%) to their portfolio in Q2 2025, for an estimated $1,833,706
- BLUE OWL CAPITAL HOLDINGS LP added 125,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,561,250
- EVENTIDE ASSET MANAGEMENT, LLC removed 117,556 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,046,649
- CITADEL ADVISORS LLC added 97,396 shares (+38.5%) to their portfolio in Q2 2025, for an estimated $1,216,476
- ALLY BRIDGE GROUP (NY) LLC added 94,500 shares (+158.2%) to their portfolio in Q2 2025, for an estimated $1,180,305
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KRRO Analyst Ratings
Wall Street analysts have issued reports on $KRRO in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 08/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 07/24/2025
- Oppenheimer issued a "Outperform" rating on 05/13/2025
- Cantor Fitzgerald issued a "Overweight" rating on 04/29/2025
- RBC Capital issued a "Outperform" rating on 03/19/2025
To track analyst ratings and price targets for $KRRO, check out Quiver Quantitative's $KRRO forecast page.
$KRRO Price Targets
Multiple analysts have issued price targets for $KRRO recently. We have seen 7 analysts offer price targets for $KRRO in the last 6 months, with a median target of $90.0.
Here are some recent targets:
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $90.0 on 08/13/2025
- Steven Seedhouse from Raymond James set a target price of $147.0 on 08/13/2025
- Keay Nakae from Chardan Capital set a target price of $25.0 on 08/13/2025
- Andreas Argyrides from Oppenheimer set a target price of $90.0 on 05/13/2025
- Steven Seedhouse from Cantor Fitzgerald set a target price of $74.0 on 04/29/2025
- Luca Issi from RBC Capital set a target price of $95.0 on 03/19/2025
Full Release
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September:
Citi's 2025 Biopharma Back to School Conference
Ram Aiyar, Ph.D., Chief Executive Officer and President, and Loic Vincent, Ph.D., Chief Scientific Officer, will participate in 1x1 investor meetings on Wednesday, September 3, 2025.
Cantor Global Healthcare Conference
Dr. Aiyar will participate in a fireside chat on Thursday, September 4, 2025, at 3:55 p.m. ET. Vineet Agarwal, Chief Financial Officer, will also participate in 1x1 investor meetings at the conference.
2025 Wells Fargo Securities Healthcare Conference
Dr. Vincent and Todd Chappell, Chief Operating Officer, will participate in 1x1 investor meetings on Friday, September 5, 2025.
H.C. Wainwright 27
th
Annual Global Investment Conference
Mr. Agarwal and Mr. Chappell will participate in 1x1 investor meetings on Monday, September 8, 2025.
Morgan Stanley 23
rd
Annual Global Healthcare Conference
Mr. Agarwal and Mr. Chappell will participate in 1x1 investor meetings on Monday, September 8, 2025.
RNA Leaders USA Congress
Mr. Chappell will deliver a presentation titled, “Developing Novel RNA Editing Therapies to Address Unmet Needs for Rare and Highly Prevalent Diseases,” on Thursday, September 11, 2025, at 11:45 a.m. ET.
About Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Korro Bio Contact Information
Investors
[email protected]
Media
Glenn Silver
FINN Partners
[email protected]
This press release was published by a CLEAR® Verified individual.
